Bosch develops rapid test for COVID-19

Reliable test results enable differential diagnosis in under 2.5 hours

159
Bosch
A sample is taken from the patient’s nose or throat using a swab. Then the cartridge is inserted into the Vivalytic device for analysis. The Vivalytic analyzer is designed to be so user-friendly that even medical personnel who have not been specially trained on it can reliably perform the test. Photo - Bosch

The coronavirus SARS-CoV-2 is posing major challenges for healthcare systems and medical institutions worldwide. An ability to rapidly diagnose the virus is of invaluable help in curbing its exponential spread in many countries. Bosch’s new, fully automated rapid test for COVID-19 can help medical facilities such as doctors’ offices, hospitals, laboratories, and health centers make fast diagnoses. The rapid molecular diagnostic test runs on the Vivalytic analysis device from Bosch Healthcare Solutions. “We want the Bosch rapid COVID-19 test to play a part in containing the coronavirus pandemic as quickly as possible. It will speed up the identification and isolation of infected patients,” says Volkmar Denner, chairman of the board of management of Robert Bosch GmbH. “Bosch’s rapid COVID-19 test will help contain the spread of the pandemic and break the chain of transmission more quickly.”

200324 analyser4 kartuschen qr vri kartusche blanco 16 9 img h900
The COVID-19-(SARS-CoV-2-) rapid testing kit for the Vivalytic analysis device from Bosch delivers reliable results at the point of care in less than 2.5 hours. Bosch’s new, fully automated rapid test for COVID-19 can help medical facilities such as doctors’ offices, hospitals, laboratories, and health centers make fast diagnoses. Photo – Bosch

Faster certainty, slower spread

Developed in just six weeks, the rapid test can detect a SARS-CoV-2 coronavirus infection in patients in under two and a half hours – measured from the time the sample is taken to the time the result arrives. Another advantage of the rapid test is that it can be performed directly at the point of care. This eliminates the need to transport samples, which takes up valuable time. It also means patients quickly gain certainty about their state of health while allowing infected individuals to be identified and isolated immediately. With the tests currently in use, patients must usually wait for one to two days for a result. “Time is of the essence in the fight against coronavirus. Reliable, rapid diagnosis directly on-site with no back and forth – that is the great advantage of our solution, which we see as another example of technology that is ‘Invented for life,” Denner says.

Differential diagnosis: diagnosing ten respiratory pathogens simultaneously

Bosch’s rapid test is one of the world’s first fully automated molecular diagnostic tests that can be used directly by all medical institutions. What’s more, it allows a single sample to be tested not just for COVID-19 but also for nine other respiratory diseases, including influenza A and B, simultaneously. “The special feature of the Bosch test is that it offers differential diagnosis, which saves doctors the additional time needed for further tests. It also provides them with a reliable diagnosis quickly so they can then begin suitable treatment faster,” says Marc Meier, president of Bosch Healthcare Solutions GmbH. The newly developed test will be available in Germany starting in April, with other markets in Europe and elsewhere to follow.

Bosch’s rapid COVID-19 test is the result of a collaboration between the company’s Bosch Healthcare Solutions subsidiary and the Northern Irish medical technology company Randox Laboratories. “Together with our partner Randox, we have succeeded in developing this innovative rapid test within a short time frame, and we are now in a position to offer it to the market. The Bosch Vivalytic analysis device evaluates the test safely and reliably directly in the hospital, in the lab, or in the doctor’s office, guaranteeing the best possible protection for patients and medical staff,” Meier says. The company is currently examining how it can help doctors and nursing staff in medical facilities such as the Robert Bosch Hospital get tested promptly so they can be fit to work for as long as possible – with no risk of infecting others.

Easy application at the point of care

In various laboratory tests with SARS-CoV-2, the Bosch test delivered results with an accuracy of over 95%. The rapid test meets the quality standards of the World Health Organization (WHO). A sample is taken from the patient’s nose or throat using a swab. Then the cartridge, which already contains all the reagents required for the test, is inserted into the Vivalytic device for analysis.

During the analysis, medical staff can devote themselves to other tasks, for example, treating patients. The Vivalytic analyzer is designed to be so user-friendly that even medical personnel who have not been specially trained on it can reliably perform the test. A Bosch Vivalytic analyzer can perform up to ten tests in the space of 24 hours. This means it takes just 100 devices to evaluate up to 1,000 tests per day. Given the dynamic spread of the coronavirus SARS-CoV-2, laboratories are already working beyond capacity. The Bosch Vivalytic will thus help to increase available testing capacities.

The impact, resilience, and growth of responsible packaging in a wide region are daily chronicled by Packaging South Asia.

A multi-channel B2B publication and digital platform such as Packaging South Asia is always aware of the prospect of new beginnings and renewal. Its 16-year-old print monthly, based in New Delhi, India has demonstrated its commitment to progress and growth. The Indian and Asian packaging industries have shown resilience in the face of ongoing challenges over the past three years.

As we present our publishing plan for 2023, India’s real GDP growth for the financial year ending 31 March 2023 will reach 6.3%. Packaging industry growth has exceeded GDP growth even when allowing for inflation in the past three years.

The capacity for flexible film manufacturing in India increased by 33% over the past three years. With orders in place, we expect another 33% capacity addition from 2023 to 2025. Capacities in monocartons, corrugation, aseptic liquid packaging, and labels have grown similarly. The numbers are positive for most of the economies in the region – our platform increasingly reaches and influences these.

Even given the disruptions of supply chains, raw material prices, and the challenge of responsible and sustainable packaging, packaging in all its creative forms and purposes has significant headroom to grow in India and Asia. Our context and coverage engulf the entire packaging supply chain – from concept to shelf and further – to waste collection and recycling. We target brand owners, product managers, raw material suppliers, packaging designers and converters, and recyclers.

In an admittedly fragmented and textured terrain, this is the right time to plan your participation and marketing support communication – in our impactful and highly targeted business platform. Tell us what you need. Speak and write to our editorial and advertising teams! For advertisement ads1@ippgroup.in , for editorial info@ippgroup.in and for subscriptions subscription@ippgroup.in

– Naresh Khanna

Subscribe Now
unnamed 1

NEWSLETTER

Subscribe to our Newsletter

As 2023 begins and FY 23-24 unfolds, will you support us?

What lies in store for the packaging industry in India and South Asia this coming year? Inflation, disruption of supply chains or environmental regulation? Or the resumption of high rural demand, continued investment and industry consolidation? Whatever happens, Packaging South Asia will be there, providing clarity and independent technical and business information in India and South Asia and around the world. We are a compact Indian organization bringing a window of fair and rigorous technical and business information that the industry can access this year and beyond. Please support us with your advertising and subscriptions, to keep us going and growing.

Thank you.

LEAVE A REPLY

Please enter your comment!
Please enter your name here